គេហទំព័រព័ត៌មានកម្ពុជា

Day: ខែ​ឧសភា 29, 2025

Modern Dental Group’s Thai Subsidiary Hexa Ceram Held 30th Anniversary Celebration and Dental Symposium

admin

HONG KONG, May 28, 2025 – (ACN Newswire via SeaPRwire.com) – Modern Dental Group Limited (“Modern Dental” or “the Group”, stock code: 03600.HK), a leading global dental prosthetic devices provider, announced the successful launch of the 30th Anniversary Celebration and Symposium “Hexallence Beyond 30: Pioneering Tomorrow’s Dentistry” by its Thai subsidiary Hexa Ceram Dental Laboratory (“Hexa Ceram”) in Bangkok, Thailand on 24th May. As a crucial segment of Modern Dental Group’s strategic framework in the Asia-Pacific region, Hexa Ceram’s 30th anniversary celebration is not only a milestone for the industry but also marks a new starting point for the collaborative development of both parties.In the 30 years since its establishment in 1995, Hexa Ceram has been committed to promoting innovation in dental technology. By 2023, its local market share reached 29%, making it the top dental laboratory in Thailand. It has become a benchmark company in the dental field in Thailand and Southeast Asia. Themed “Pioneering …

New Drug Approval for In-House Developed Anti-Insomnia Drug DAYVIGO (Lemborexant) in China

admin

TOKYO, May 28, 2025 – (JCN Newswire via SeaPRwire.com) – Eisai Co., Ltd. announced today that the in-house-discovered and developed orexin receptor antagonist DAYVIGO® (generic name: lemborexant) has been approved in China for the treatment of adults with insomnia, characterized by difficulties with sleep onset and/or sleep maintenance. Eisai plans to launch this medicine in China in the second quarter of fiscal year 2025.DAYVIGO is a dual orexin receptor antagonist that inhibits orexin neurotransmission regulating sleep-wake rhythm by binding competitively to the two subtypes of orexin receptors (OX1R and OX2R). DAYVIGO acts on the orexin neurotransmitter system and is believed to facilitate sleep onset, sleep maintenance, and wake by regulating sleep-wake rhythm. DAYVIGO binds to orexin receptors OX1R and OX2R and acts as a competitive antagonist with stronger inhibition effect on OX2R, which suppresses both REM and non-REM sleep drive, such that DAYVIGO may provide faster sleep onset and better sleep maint…

GK Software becomes a Fujitsu company

admin

KAWASAKI, Japan, May 28, 2025 – (JCN Newswire via SeaPRwire.com) – Fujitsu Limited today announced the successful completion of the acquisition of GK Software, which is now a wholly owned subsidiary of the Fujitsu Group.With the transaction now complete, a new and exciting chapter begins. GK, which currently serves more than a quarter of the world’s top 50 retailers across 60 countries, has strong brand recognition in the retail industry, leading the global market with industry-leading POS and SaaS solutions including AI-powered price optimization. The two companies will strengthen their cooperation with Fujitsu contributing its technology to GK, including Fujitsu Kozuchi, Data Intelligence PaaS, and Dynamic SCM, and global delivery capabilities such as high-precision demand forecasting, which will increase added value for customers. GK’s retail technology will underpin the Consumer Experience pillar of Fujitsu Uvance – Fujitsu solutions that accelerate business and address societal challenges – and strengthe…

Euro Manganese Closes C$11.2 million (A$12.3 million) Financing

admin

Highlights Financing included an upsized C$9.8 million (A$10.8 million) Private Placement and an oversubscribed A$1.5 million (C$1.4 million) Share Purchase PlanCompany welcomes the European Bank of Reconstruction and Development and Eric Sprott as significant shareholdersFunds raised to support ongoing development of the Chvaletice Manganese Project and customer engagements to secure additional offtake term sheets and strategic investmentsVancouver, British Columbia–(ACN Newswire via SeaPRwire.com – May 28, 2025) – Euro Manganese Inc. (TSXV) (ASX: EMN) (FSE: E060) (the “Company” or “Euro Manganese”) is pleased to announce that, following the approval by its shareholders at its Annual General and Special Meeting held on May 15, 2025 (the “AGSM”), it has closed the previously announced financing package which included: (a) a private placement (the “Placement”) of common shares (“New Shares”) and CHESS Depositary Interests (“New CDIs” together with the New Shares, “New Securities”) in the capital of the Compan…